机译:升高的中性粒细胞到淋巴细胞比率预测,用曲妥珠单抗组合化疗治疗晚期胃癌患者的存活
Kyungpook Natl Univ Dept Oncol Hematol Sch Med Canc Res Inst Daegu South Korea;
Kyungpook Natl Univ Dept Oncol Hematol Sch Med Canc Res Inst Daegu South Korea;
Kyungpook Natl Univ Dept Oncol Hematol Sch Med Canc Res Inst Daegu South Korea;
Kyungpook Natl Univ Dept Oncol Hematol Sch Med Canc Res Inst Daegu South Korea;
Kyungpook Natl Univ Dept Oncol Hematol Sch Med Canc Res Inst Daegu South Korea;
Kyungpook Natl Univ Dept Oncol Hematol Sch Med Canc Res Inst Daegu South Korea;
Kyungpook Natl Univ Dept Oncol Hematol Sch Med Canc Res Inst Daegu South Korea;
Kyungpook Natl Univ Dept Oncol Hematol Sch Med Canc Res Inst Daegu South Korea;
Kyungpook Natl Univ Hosp Daegu South Korea;
Kyungpook Natl Univ Hosp Daegu South Korea;
Kyungpook Natl Univ Hosp Daegu South Korea;
Kyungpook Natl Univ Hosp Daegu South Korea;
Kyungpook Natl Univ Hosp Daegu South Korea;
Kyungpook Natl Univ Hosp Daegu South Korea;
Kyungpook Natl Univ Hosp Daegu South Korea;
Gastric cancer; trastuzumab; neutrophil-to-lymphocyte ratio; prognostic factor;
机译:升高的中性粒细胞到淋巴细胞比率预测,用曲妥珠单抗组合化疗治疗晚期胃癌患者的存活
机译:术前中性白细胞/淋巴细胞比率升高可预测接受胃癌根治术的早期胃癌患者的不良生存:福建省癌症前瞻性研究(FIESTA)研究
机译:曲妥珠单抗联合化疗治疗HER2阳性晚期胃癌患者血清HER2 ECD的预测价值(第50卷,第955页,2015年)
机译:手术细胞凝固可以改善化疗后的疗法疗法,并维持晚期胃癌患者的QoL
机译:晚期胃癌患者化学疗法的治疗模式和成本效益
机译:外周静脉血中性粒细胞与淋巴细胞比值预测新辅助化疗治疗的晚期胃癌患者的生存
机译:外周静脉血液中性粒细胞对淋巴细胞比率预测新辅助化疗治疗晚期胃癌患者的存活